Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Research Abstract |
In patients with CD20 positive B-cell non-Hodgkin lymphoma who underwent yttrium-90 labeled anti-CD20 ibritumomab tiuxetan therapy, glucose metabolism by FDG and hypoxia by FMISO were evaluated with PET/CT before and after therapy, and changes were analyzed over time. Antigen expression of CD20 was also evaluated by SPECT/CT using indium-111 labeled anti-CD20 antibody. Association of glucose metabolism, hypoxia, and CD20 expression with therapeutic response was analyzed.
|